Lance Baldo is Chief Medical Officer at Adaptive Biotechnologies Corp (ADPT). They have made 13 open-market trades across 1 company since 2020, most recently 2022-03-08.
CIK 0001780773
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADPT | 17,171 | $459K |
Shares reported on the most recent Form 4, priced at the 2022-03-10 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADPT | SELL · 10b5-1 | 2022-03-08 | 2022-03-10 | $11.43 | $38K | +9.7% | -0.8% | -36.0% |
| ADPT | SELL | 2022-03-07 | 2022-03-08 | $12.01 | $28K | +5.6% | +8.7% | -43.9% |
| ADPT | SELL | 2021-04-14 | 2021-04-16 | $44.50 | $89K | +5.2% | -16.6% | -14.6% |
| ADPT | SELL | 2021-01-27 | 2021-01-29 | $58.95 | $4.7M | +12.0% | +3.3% | -23.5% |
| ADPT | SELL | 2020-12-07 | 2020-12-09 | $50.65 | $442K | +20.7% | +16.7% | -20.4% |
| ADPT | SELL | 2020-11-06 | 2020-11-10 | $50.59 | $592K | -5.3% | +12.8% | +25.2% |
| ADPT | SELL | 2020-10-06 | 2020-10-07 | $49.20 | $615K | -2.7% | +0.4% | +9.1% |
| ADPT | SELL | 2020-09-29 | 2020-10-01 | $50.00 | $1.3M | +9.7% | -5.4% | +22.6% |
| ADPT | SELL | 2020-09-10 | 2020-09-11 | $40.00 | $167K | +19.8% | +31.4% | +37.5% |
| ADPT | SELL | 2020-09-08 | 2020-09-09 | $36.17 | $151K | +23.1% | +36.2% | +37.4% |
| ADPT | SELL | 2020-08-06 | 2020-08-07 | $40.00 | $250K | +12.8% | -5.3% | +33.2% |
| ADPT | SELL | 2020-07-06 | 2020-07-08 | $47.31 | $582K | -16.9% | -21.4% | +0.4% |
| ADPT | SELL | 2020-06-08 | 2020-06-10 | $39.51 | $325K | +9.0% | +8.8% | -14.2% |
| ADPT | SELL | 2020-05-06 | 2020-05-08 | $33.85 | $3.4M | +11.4% | +8.9% | +10.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.